CLOPIDOGREL BISULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H16ClNO2S.H2O4S
Molecular Weight	419.9
Optical Activity	( + )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=CC=CC=C3Cl

InChI

InChIKey=FDEODCTUSIWGLK-RSAXXLAASA-N

InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4)/t15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H16ClNO2S
Molecular Weight	321.822
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf | https://www.drugbank.ca/drugs/DB00758 | https://www.ncbi.nlm.nih.gov/pubmed/15199474

Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Purinergic receptor P2Y12 23 Target ID: CHEMBL2001 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15199474 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf \| https://www.drugbank.ca/drugs/DB00758	Antagonist 2737		6.9 null [pKi]
Purinergic receptor P2Y12 23 Target ID: CHEMBL2001 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0078fb3d-3595-4ae1-a059-1d5e81c879cf&type=display\|https://www.ncbi.nlm.nih.gov/pubmed/10446085	Antagonist 2737

Conditions

Condition	Modality	Highest Phase	Product
Atherosclerosis 74 Sources: https://www.drugs.com/pro/clopidogrel.html	Primary	Approved 8307	PLAVIX Approved Use Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Launch Date 8.7972479E11
Acute coronary syndrome 32 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf	Primary	Approved 8307	PLAVIX Approved Use Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Launch Date 8.7963841E11
Peripheral arterial disease 22 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf	Primary	Approved 8307	PLAVIX Approved Use Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Launch Date 8.7972479E11
Myocardial infarction 103 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf	Preventing	Approved 8307	PLAVIX Approved Use Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Launch Date 8.7972479E11

C_max

Value	Dose	Analyte	Population
1500 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15800 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2520 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4600 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.521 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534	75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered:	CLOPIDOGREL plasma	Homo sapiens population: healthy age: sex: food status:

AUC

Value	Dose	Analyte	Population
3130 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
50600 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7440 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
9890 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.767 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534	75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered:	CLOPIDOGREL plasma	Homo sapiens population: healthy age: sex: food status:
1.09 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534	75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered:	CLOPIDOGREL plasma	Homo sapiens population: healthy age: sex: food status:

T_1/2

Value	Dose	Analyte	Population
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	CLOPIDOGREL BISULFATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf	unknown, unknown		CLOPIDOGREL BISULFATE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26063503	healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: https://pubmed.ncbi.nlm.nih.gov/26063503	Other AEs: Uric acid abnormal... Other AEs: Uric acid abnormal (5 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26063503
1650 mg single, oral Overdose Dose: 1650 mg Route: oral Route: single Dose: 1650 mg Co-administed with:: phenytoin sodium(1400 mg; single) simvastatin(120 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/17286151	unknown, 49 years n = 1 Health Status: unknown Age Group: 49 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17286151	Sources: https://pubmed.ncbi.nlm.nih.gov/17286151
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16878371	unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16878371	Disc. AE: Transaminases increased, Fever... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Fever (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/16878371

AEs

AE	Significance	Dose	Population
Uric acid abnormal	5 patients	600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26063503	healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: https://pubmed.ncbi.nlm.nih.gov/26063503
Fever	1 patient Disc. AE	600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16878371	unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16878371
Transaminases increased	1 patient Disc. AE	600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16878371	unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16878371

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:37941	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:37941
MolPort	MolPort-002-885-817	https://www.molport.com/shop/molecule-link/MolPort-002-885-817
ZINC	ZINC000034781704	http://zinc15.docking.org/substances/ZINC000034781704
eMolecules	2735330	https://www.emolecules.com/cgi-bin/more?vid=2735330

PubMed

Title	Date	PubMed
Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers.	1998	10366994
Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.	1999 Aug	10446085
Drug-induced thrombotic microangiopathy: incidence, prevention and management.	2001	11444722
Novel platelet inhibitors.	2001	11160773
Aspirin in patients with coronary artery disease: is it simply irresistible?	2001 Apr	11406726
Regular or "super-aspirins"? A review of thienopyridines or aspirin to prevent stroke.	2001 Apr	11347797
Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease.	2001 Apr	11286524
Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention.	2001 Apr	11250982
Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data.	2001 Aug	11487380
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.	2001 Jan	11119474
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.	2001 Jan 23	11157686
[Can we use clopidogrel in patients with coronary stent?].	2001 Jan-Mar	11488209
Multiple intracranial aneurysms as delayed complications of an atrial myxoma: case report.	2001 Jul	11440443
Extensive thrombus prior to elective percutaneous coronary intervention.	2001 Jul	11435643
Diffuse alveolar hemorrhage after clopidogrel use.	2001 Jul	11435642
The P2Y12 receptor as a therapeutic target in cardiovascular disease.	2001 Jun	11454254
[Toxic skin reaction to clopidogrel].	2001 Jun	11431626
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen.	2001 Jun 15	11419889
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.	2001 Jun 21	11419425
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].	2001 Mar 29	11550619
What is the optimal medical management of ischemic heart failure?	2001 Mar-Apr	11251129
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.	2001 May	11346067
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.	2001 May	11301411
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.	2001 May 1	11331266
P2y(12), a new platelet ADP receptor, target of clopidogrel.	2001 May 4	11327712
Antiplatelet agents for secondary prevention of ischemic stroke.	2001 Oct	11675854
Coronary stent thrombosis: insights from the porcine coronary stent model.	2001 Sep	11583335
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.	2001 Sep	11573862
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.	2001 Sep 15	11564394
Clopidogrel versus aspirin after cardiac surgery.	2001 Sep 25	11571262

Patents

Sample Use Guides

In Vivo Use Guide

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease The recommended daily dose of is 75 mg once daily.

Route of Administration: Oral

In Vitro Use Guide

Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:39:57 UTC 2022` Edited by `admin` on `Fri Dec 16 17:39:57 UTC 2022`
Record UNII	08I79HTP27
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLOPIDOGREL BISULFATE

Official Name

English

METHYL (+)-(S)-.ALPHA.-(O-CHLOROPHENYL)-6,7-DIHYDROTHIENO(3,2-C)PYRIDINE-5(4H)-ACETATE, SULPHATE (1:1)

Common Name

English

CLOPIDOGREL BISULFATE COMPONENT OF DUOCOVER

Brand Name

English

CLOPIDOGREL-BMS

Brand Name

English

CLOPIDOGREL HYDROGEN SULPHATE

Common Name

English

CLOPIDOGREL TEVA

Brand Name

English

CLOPIDOGREL-BGR

Brand Name

English

PLAVIX

Brand Name

English

CLOPIDOGREL BISULFATE [USP-RS]

Common Name

English

CLOPIDOGREL BMS

Brand Name

English

CLOPIDOGREL BISULPHATE

Common Name

English

CLOPIDOGREL HYDROGEN SULFATE [MI]

Common Name

English

CLOPIDOGREL HYDROGEN SULFATE [EP MONOGRAPH]

Common Name

English

Clopidogrel bisulfate [WHO-DD]

Common Name

English

CLOPIDOGREL RATIOPHARM

Brand Name

English

CLOPIDOGREL HYDROGEN SULFATE [EMA EPAR]

Common Name

English

ISOCOVER

Brand Name

English

CLOPIDOGREL (AS BISULFATE)

Common Name

English

PIDOGREL

Brand Name

English

CLOPIDOGREL BISULFATE [ORANGE BOOK]

Common Name

English

CLOPIDOGREL BISULFATE [USP MONOGRAPH]

Common Name

English

THIENO(3,2-C)PYRIDINE-5(4H)-ACETIC ACID, .ALPHA.-(2-CHLOROPHENYL)-6,7-DIHYDRO-, METHYL ESTER, (S)-, SULFATE (1:1)

Common Name

English

CLOPIDOGREL (AS HYDROGEN SULFATE)

Common Name

English

CLOPIDOGREL HYDROGEN SULPHATE [EMA EPAR]

Common Name

English

CLOPIDOGREL BISULFATE COMPONENT OF DUOPLAVIN

Brand Name

English

CLOPIDOGREL ZENTIVA

Brand Name

English

CLOPIDOGREL/ACETYLSALICYCLIC ACID TEVA COMPONENT CLOPIDOGREL BISULFATE

Brand Name

English

CLOPIDOGREL BISULFATE [MART.]

Common Name

English

CLOPIDOGREL SULFATE [JAN]

Common Name

English

SR-25990C

Code

English

SR 25990C

Code

English

CLOPIDOGREL BISULFATE [USAN]

Common Name

English

DUOCOVER COMPONENT CLOPIDOGREL BISULFATE

Brand Name

English

METHYL (+)-(S)-.ALPHA.-(O-CHLOROPHENYL)-6,7-DIHYDROTHIENO(3,2-C)PYRIDINE-5(4H)-ACETATE, SULFATE (1:1)

Common Name

English

DUOPLAVIN COMPONENT CLOPIDOGREL BISULFATE

Brand Name

English

THIENO(3,2-C)PYRIDINE-5(4H)-ACETIC ACID, .ALPHA.-(2-CHLOROPHENYL)-6,7-DIHYDRO-, METHYL ESTER, (S)-, SULPHATE (1:1)

Common Name

English

CLOPIDOGREL HYDROGEN SULFATE

Common Name

English

CLOPIDOGREL BISULFATE COMPONENT OF CLOPIDOGREL/ACETYLSALICYCLIC ACID TEVA

Brand Name

English

CLOPIDOGREL BISULFATE [VANDF]

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

PLAVIX (AUTHORIZED: ATRIAL FIBRILLATION)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL TEVA (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

PLAVIX (AUTHORIZED: MYOCARDIAL INFARCTION)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL TEVA (AUTHORIZED: STROKE)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

NCI_THESAURUS

C80483

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL ZENTIVA (AUTHORIZED: MYOCARDIAL INFARCTION)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

ZYLLT (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

PLAVIX (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL TEVA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

ZYLLT (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

ZYLLT (AUTHORIZED: MYOCARDIAL INFARCTION)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL-BMS (WITHDRAWN: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

ZYLLT (AUTHORIZED: STROKE)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL ZENTIVA (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

ISOCOVER (AUTHORIZED: ATRIAL FIBRILLATION)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

ISCOVER (AUTHORIZED: MYOCARDIAL INFARCTION)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL RATIOPHARM (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

DUOCOVER (AUTHORIZED: MYOCARDIAL INFARCTION)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL ZENTIVA (AUTHORIZED: STROKE)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL-BMS (WITHDRAWN: STROKE)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

DUOPLAVIN (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL ZENTIVA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

PLAVIX (AUTHORIZED: STROKE)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL/ACETYLSALICYLIC ACID (AUTHORIZED: MYOCARDIAL INFARCTION)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL-BGR (AUTHORIZED: STROKE)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL-BMS (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

DUOPLAVIN (AUTHORIZED: MYOCARDIAL INFARCTION)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL BMS (WITHDRAWN: MYOCARDIAL INFARCTION)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL RATIOPHARM (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL/ACETYLSALICYCLIC ACID TEVA (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

CLOPIDOGREL RATIOPHARM (AUTHORIZED: STROKE)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

DUOCOVER (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

EMA ASSESSMENT REPORTS

ISCOVER (AUTHORIZED: ACUTE CORONARY SYNDROME)

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

Code System Code Type Description

CAS

120202-66-6

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

PRIMARY

MERCK INDEX

M3655

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

PRIMARY

Merck Index

RXCUI

236991

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

PRIMARY

RxNorm

ChEMBL

CHEMBL1771

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

PRIMARY

CHEBI

3759

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

PRIMARY

FDA UNII

08I79HTP27

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

PRIMARY

EVMPD

SUB12483MIG

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

PRIMARY

DAILYMED

08I79HTP27

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

PRIMARY

CAS

135046-48-9

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

NON-SPECIFIC STEREOCHEMISTRY

EPA CompTox

DTXSID4046024

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

PRIMARY

NCI_THESAURUS

C2673

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

PRIMARY

RS_ITEM_NUM

1140430

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

PRIMARY

PUBCHEM

115366

Created by admin on Fri Dec 16 17:39:58 UTC 2022 , Edited by admin on Fri Dec 16 17:39:58 UTC 2022

PRIMARY

DRUG BANK

DBSALT000029

Created by admin on Fri Dec 16 17:39:57 UTC 2022 , Edited by admin on Fri Dec 16 17:39:57 UTC 2022

PRIMARY

Related Record Type Details


					A74586SNO7

CLOPIDOGREL

PARENT -> SALT/SOLVATE

Amount:


					39KXS67R6V

CLOPIDOGREL BISULFATE, (R)-

ENANTIOMER -> ENANTIOMER

Amount:

Related Record Type Details


					1B9Z4634CD

CLOPIDOGREL CARBOXYLIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					M3CHA6RU6P

METHYL .ALPHA.-(2-CHLOROPHENYL)-4,7-DIHYDROTHIENO(2,3-C)PYRIDINE-6(5H)-ACETATE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

Related Record Type Details


					A74586SNO7

CLOPIDOGREL

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf | https://www.drugbank.ca/drugs/DB00758 | https://www.ncbi.nlm.nih.gov/pubmed/15199474

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf | https://www.drugbank.ca/drugs/DB00758 | https://www.ncbi.nlm.nih.gov/pubmed/15199474

C_max

T_1/2

F_unbound